Lizanne Eva van den Akker1, Martin Heine2, Nikki van der Veldt3, Joost Dekker4, Vincent de Groot4, Heleen Beckerman4. 1. Department of Rehabilitation Medicine, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; EMGO Institute for Health and Care Research, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands. Electronic address: l.vandenakker@vumc.nl. 2. Rudolf Magnus Institute of Neuroscience and Center of Excellence for Rehabilitation Medicine, University Medical Center Utrecht and Rehabilitation Center De Hoogstraat, Utrecht, The Netherlands. 3. Department of Rehabilitation Medicine, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; Faculty of Medicine, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands. 4. Department of Rehabilitation Medicine, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; EMGO Institute for Health and Care Research, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: To investigate the feasibility and safety of cardiopulmonary exercise testing (CPET) in patients with multiple sclerosis (MS). DATA SOURCES: PubMed, EMBASE, CINAHL, SPORTDiscus, PsycINFO, ERIC, and the Psychology and Behavioral Sciences Collection were searched up to October 2014. References from retrieved articles were examined to identify additional relevant studies. STUDY SELECTION: Inclusion of original studies was on the basis of performance of maximal CPET, description of the protocol, and participants with definite MS aged ≥18 years. No language restrictions were applied. DATA EXTRACTION: The quality of CPET reporting in included studies was scored according to a structured checklist considering 10 feasibility (eg, test abnormalities) and 12 safety quality criteria (eg, adverse events). Structured data extraction was performed for these feasibility and safety features of CPET. DATA SYNTHESIS: Forty-six studies were included, comprising 1483 patients with MS, with a mean age ± SD of 42.0±5.8 years and a median Expanded Disability Status Scale (EDSS) score of 2.8 (first quartile=2.1; third quartile=3.9; range of average EDSS scores, .75-5.8). Quality of reporting on CPET varied from 3 to 13 out of a possible 22 quality points. The percentage of test abnormalities (feasibility) was 10.0%, primarily because of an inability to maintain pedaling at a specific resistance. The percentage of adverse events (safety) was 2.1%. All adverse events were temporary. CONCLUSIONS: Based on the available data, we conclude that CPET is feasible provided that the CPET modality is tailored to the physical abilities of the patient. Furthermore, CPET is safe when recommended precautions and safety measures are implemented. However, future optimization of CPET will require protocolized testing and the implementation of standard reporting procedures.
OBJECTIVE: To investigate the feasibility and safety of cardiopulmonary exercise testing (CPET) in patients with multiple sclerosis (MS). DATA SOURCES: PubMed, EMBASE, CINAHL, SPORTDiscus, PsycINFO, ERIC, and the Psychology and Behavioral Sciences Collection were searched up to October 2014. References from retrieved articles were examined to identify additional relevant studies. STUDY SELECTION: Inclusion of original studies was on the basis of performance of maximal CPET, description of the protocol, and participants with definite MS aged ≥18 years. No language restrictions were applied. DATA EXTRACTION: The quality of CPET reporting in included studies was scored according to a structured checklist considering 10 feasibility (eg, test abnormalities) and 12 safety quality criteria (eg, adverse events). Structured data extraction was performed for these feasibility and safety features of CPET. DATA SYNTHESIS: Forty-six studies were included, comprising 1483 patients with MS, with a mean age ± SD of 42.0±5.8 years and a median Expanded Disability Status Scale (EDSS) score of 2.8 (first quartile=2.1; third quartile=3.9; range of average EDSS scores, .75-5.8). Quality of reporting on CPET varied from 3 to 13 out of a possible 22 quality points. The percentage of test abnormalities (feasibility) was 10.0%, primarily because of an inability to maintain pedaling at a specific resistance. The percentage of adverse events (safety) was 2.1%. All adverse events were temporary. CONCLUSIONS: Based on the available data, we conclude that CPET is feasible provided that the CPET modality is tailored to the physical abilities of the patient. Furthermore, CPET is safe when recommended precautions and safety measures are implemented. However, future optimization of CPET will require protocolized testing and the implementation of standard reporting procedures.
Authors: Susan Coote; Marcin Uszynski; Matthew P Herring; Sara Hayes; Carl Scarrott; John Newell; Stephen Gallagher; Aidan Larkin; Robert W Motl Journal: BMC Neurol Date: 2017-06-24 Impact factor: 2.474